文献速递妇科

子宫内膜异位症相关痛经阶梯式管理的成本效果分析

Stepwise Approach to the Management of Endometriosis-Related Dysmenorrhea: A Cost-Effectiveness Analysis.
PubMed 文献 · Obstet Gynecol · 2021-01-01

本研究采用成本效果模型,从医疗支付方角度比较三种阶梯式药物与手术治疗策略与直接手术的成本效果。理论队列为美国4,817,894名18-45岁子宫内膜异位症相关痛经女性。结果显示所有阶梯策略在100,000美元/QALY阈值下均具成本效果,策略2(NSAIDs后短效或长效可逆避孕药再手术)每获得QALY成本最低(1,155美元)。

要点

  • 所有阶梯式药物手术策略相比直接手术均具成本效果。
  • 策略2(NSAIDs后避孕药再手术)每QALY成本最低。
  • 手术改善概率需超过83%才可能成为首选一线方案。

核心结论

  • 所有序贯药物与手术管理策略相比单纯手术均具成本效果。
  • NSAIDs后尝试激素管理再手术可能节省成本。
  • 对超过三种药物无效的疼痛患者延迟手术可能降低生活质量并增加成本。

研究设计与样本

  • 成本效果模型,从医疗支付方角度比较三种阶梯式药物手术策略与直接手术。
  • 理论队列基于美国18-45岁子宫内膜异位症相关痛经女性估计数,共4,817,894人。

主要发现

  • 在100,000美元/QALY支付意愿阈值下,所有药物手术策略相比单纯手术均具成本效果。
  • 策略2每获得QALY成本最低,为1,155美元。
  • 手术改善概率需超过83%才可能成为首选一线方案。

关键数值与推荐

  • 支付意愿阈值:100,000美元/QALY。
  • 策略2每QALY成本:1,155美元。
  • 手术成为首选一线方案所需改善概率:>83%。

临床怎么用

  • 对子宫内膜异位症相关痛经可优先尝试NSAIDs后激素管理再考虑手术。
  • 避免对超过三种药物无效者延迟手术,以免降低生活质量并增加成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the cost effectiveness of sequential medical and surgical therapy for the treatment of endometriosis-related dysmenorrhea. METHODS: A cost-effectiveness model was created to compare three stepwise medical and surgical treatment strategies compared with immediate surgical management for dysmenorrhea using a health care payor perspective. A theoretical study cohort was derived from the estimated number of reproductive age (18-45) women in the United States with endometriosis-related dysmenorrhea. The treatment strategies modeled were: strategy 1) nonsteroidal antiinflammatory drugs (NSAIDs) followed by surgery; strategy 2) NSAIDs, then short-acting reversible contraceptives or long-acting reversible contraceptives (LARCs) followed by surgery; strategy 3) NSAIDs, then a short-acting reversible contraceptive or LARC, then a LARC or gonadotropin-releasing hormone modulator followed by surgery; strategy 4) proceeding directly to surgery. Probabilities, utilities, and costs were derived from the literature. Outcomes included cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. Univariate, bivariate, and multivariate sensitivity analyses were performed. RESULTS: In this theoretical cohort of 4,817,894 women with endometriosis-related dysmenorrhea, all medical and surgical treatment strategies were cost effective at a standard willingness-to-pay threshold of $100,000 per QALY gained when compared with surgery alone. Strategy 2 was associated with the lowest cost per QALY gained ($1,155). Requiring a trial of a third medication before surgery would cost an additional $257 million, compared with proceeding to surgery after failing two medical treatments. The probability of improvement with surgery would need to exceed 83% for this to be the preferred first-line approach. CONCLUSION: All sequential medical and surgical management strategies for endometriosis-related dysmenorrhea were cost effective when compared with surgery alone. A trial of hormonal management after NSAIDs, before proceeding to surgery, may provide cost savings. Delaying surgical management in an individual with pain refractory to more than three medications may decrease quality of life and increase cost.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bohn JA, Bullard KA, Rodriguez MI, et al. Stepwise Approach to the Management of Endometriosis-Related Dysmenorrhea: A Cost-Effectiveness Analysis. Obstet Gynecol. 2021. PMID: 34623067. doi:10.1097/AOG.0000000000004536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。